NASDAQ:YMAB

Y-mAbs Therapeutics - YMAB Stock Forecast, Price & News

$14.42

+0.07 (+0.49%)

(As of 09/30/2022 09:02 PM ET)

Add

Compare

Today's Range: $14.21
▼
$15.24
50-Day Range: $13.96
▼
$18.96
52-Week Range: $6.50
▼
$29.52

Volume: 545,200 shs
Average Volume: 513,597 shs
Market Capitalization: $630.44 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $29.50

Y-mAbs Therapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 104.6% Upside
$29.50 Price Target
Short Interest: Bearish
10.94% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.31
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.88) to ($1.84) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.73 out of 5 stars

Medical Sector

952nd out of 1,095 stocks

Pharmaceutical Preparations Industry

472nd out of 547 stocks

3.3

Analyst's Opinion

Consensus Rating
Y-mAbs Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $29.50, Y-mAbs Therapeutics has a forecasted upside of 104.6% from its current price of $14.42.
Amount of Analyst Coverage
Y-mAbs Therapeutics has only been the subject of 1 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
10.94% of the float of Y-mAbs Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Y-mAbs Therapeutics has a short interest ratio ("days to cover") of 13.6, which indicates bearish sentiment.
Change versus previous month
Short interest in Y-mAbs Therapeutics has recently increased by 2.12%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Y-mAbs Therapeutics does not currently pay a dividend.
Dividend Growth
Y-mAbs Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for YMAB.

1.8

News and Social Media Coverage

News Sentiment
Y-mAbs Therapeutics has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.83 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Y-mAbs Therapeutics this week, compared to 1 article on an average week.
MarketBeat Follows
Only 1 people have added Y-mAbs Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Y-mAbs Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
20.61% of the stock of Y-mAbs Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
56.70% of the stock of Y-mAbs Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Y-mAbs Therapeutics are expected to grow in the coming year, from ($1.88) to ($1.84) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Y-mAbs Therapeutics is -4.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Y-mAbs Therapeutics is -4.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Y-mAbs Therapeutics has a P/B Ratio of 3.49. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Y-mAbs Therapeutics (NASDAQ:YMAB) Stock

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

Receive YMAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Y-mAbs Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

YMAB Stock News Headlines

September 29, 2022 | americanbankingnews.com

Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Down 2.9%

September 29, 2022 | forbes.com

Y Mabs Therapeutics

September 26, 2022 | nasdaq.com

Will Y-mAbs Therapeutics (NASDAQ:YMAB) Spend Its Cash Wisely?

September 26, 2022 | finance.yahoo.com

Y-mAbs Announces Regulatory Filing for DANYELZA® (naxitamab-gqgk) in Brazil

September 9, 2022 | finance.yahoo.com

With 55% ownership of the shares, Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) is heavily dominated by institutional owners

September 1, 2022 | finance.yahoo.com

Y-mAbs Announces Scheduling of FDA Advisory Committee Meeting for Omburtamab

August 18, 2022 | theglobeandmail.com

Instrument Name Y-Mabs Therapeutics Inc Instrument Symbol (YMAB-Q)

August 13, 2022 | uk.finance.yahoo.com

Y-mAbs Therapeutics, Inc. (YMAB)

August 12, 2022 | seekingalpha.com

Y-mAbs Therapeutics, Inc. 2022 Q2 - Results - Earnings Call Presentation

August 12, 2022 | seekingalpha.com

Y-mAbs Therapeutics, Inc. (YMAB) CEO Thomas Gad on Q2 2022 Results - Earnings Call Transcript

August 8, 2022 | finance.yahoo.com

YmAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Lags Revenue Estimates

August 2, 2022 | finance.yahoo.com

Y-mAbs to Announce Second Quarter 2022 Financial and Operating Results on August 8, 2022

July 12, 2022 | finance.yahoo.com

Y-mAbs’ Announces Clearance of IND for GD2-SADA

June 30, 2022 | finance.yahoo.com

Y-mAbs Therapeutics (NASDAQ:YMAB) shareholders have endured a 57% loss from investing in the stock a year ago

June 1, 2022 | barrons.com

Y-mAbs Announces FDA Acceptance of Biologics License Application for OMBLASTYS(R) (omburtamab) for the Treatment of Neuroblastoma for Priority Review

May 31, 2022 | seekingalpha.com

Y-mAbs Therapeutics: Steady, Small Steps Targeting Rare Cancers

May 31, 2022 | seekingalpha.com

Y-mAbs Omblastys gets FDA priority review to treat children with nerve cell cancer

May 31, 2022 | finance.yahoo.com

Y-mAbs Announces FDA Acceptance of Biologics License Application for OMBLASTYS® (omburtamab) for the Treatment of Neuroblastoma for Priority Review

May 26, 2022 | finance.yahoo.com

Y-mAbs Announces Naxitamab Chemoimmunotherapy Investigational Trial for High-Risk Neuroblastoma Meets Primary Endpoint

May 14, 2022 | seekingalpha.com

Y-mAbs Therapeutics, Inc. (YMAB) CEO Thomas Gad on Q1 2022 Results - Earnings Call Transcript

May 10, 2022 | marketwatch.com

Y-mAbs Shares Gain 20% on 1Q Revenue Increase and Company Guidance

May 9, 2022 | finance.yahoo.com

YmAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Lags Revenue Estimates

May 9, 2022 | investing.com

Y-mAbs Therapeutics Tops Q1 EPS by 8c

May 3, 2022 | finance.yahoo.com

Y-mAbs to Announce First Quarter 2022 Financial and Operating Results on May 9, 2022

April 28, 2022 | finance.yahoo.com

Earnings Preview: YmAbs Therapeutics, Inc. (YMAB) Q1 Earnings Expected to Decline

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive YMAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Y-mAbs Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

YMAB Company Calendar

Last Earnings: 8/08/2022
Today: 10/02/2022
Next Earnings (Estimated): 11/03/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:YMAB
CUSIP: N/A
CIK: 1722964
Web: www.ymabs.com
Phone: (646) 885-8505
Fax: N/A
Employees: 148
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $29.50
High Stock Price Forecast: $63.00
Low Stock Price Forecast: $17.00
Forecasted Upside/Downside: +104.6%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.09)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-55,280,000.00
Net Margins: -338.68%
Pretax Margin: -338.68%
Return on Equity: -79.40%
Return on Assets: -66.72%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.23
Quick Ratio: 5.00

Sales & Book Value

Annual Sales: $34.90 million
Price / Sales: 18.06
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.13 per share
Price / Book: 3.49

Miscellaneous

Outstanding Shares: 43,720,000
Free Float: 34,709,000
Market Cap: $630.44 million
Optionable: Not Optionable
Beta: 1.12

Key Executives

Mr. Thomas Gad (Age 52)
Founder, Interim CEO, Pres, Head of Bus. Devel. & Strategy and Director
Comp: $772.34k

Mr. Bo Kruse (Age 50)
Exec. VP, Sec., Treasurer & CFO
Comp: $638.84k

Dr. Steen Lisby M.D. (Age 58)
M.Sc., Sr. VP & Chief Scientific Officer
Comp: $393.99k

Dr. Vignesh Rajah M.B.A. (Age 57)
MBBS, Sr. VP & Chief Medical Officer
Comp: $406.27k

Mr. Joris Wiel Jan Wilms (Age 48)
Sr. VP & COO

Dr. Torben Lund-Hansen M.Sc. (Age 71)
Ph.D., Sr. VP & Head of Technical Operations

Ms. Sue Smith (Age 51)
Sr. VP & Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

YMAB Stock - Frequently Asked Questions

Should I buy or sell Y-mAbs Therapeutics stock right now?: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Y-mAbs Therapeutics in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" YMAB shares.
View YMAB analyst ratings or view top-rated stocks.
What is Y-mAbs Therapeutics' stock price forecast for 2022?: 6 Wall Street research analysts have issued 1 year target prices for Y-mAbs Therapeutics' stock. Their YMAB share price forecasts range from $17.00 to $63.00. On average, they anticipate the company's share price to reach $29.50 in the next twelve months. This suggests a possible upside of 104.6% from the stock's current price.
View analysts price targets for YMAB or view top-rated stocks among Wall Street analysts.
How have YMAB shares performed in 2022?: Y-mAbs Therapeutics' stock was trading at $16.21 at the beginning of the year. Since then, YMAB shares have decreased by 11.0% and is now trading at $14.42.
View the best growth stocks for 2022 here.
When is Y-mAbs Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our YMAB earnings forecast.
How were Y-mAbs Therapeutics' earnings last quarter?: Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) released its quarterly earnings results on Monday, August, 8th. The company reported ($0.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by $0.26. The business had revenue of $10.80 million for the quarter, compared to analyst estimates of $11.22 million. Y-mAbs Therapeutics had a negative net margin of 338.68% and a negative trailing twelve-month return on equity of 79.40%. The company's revenue for the quarter was down 1.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.53) EPS.
What guidance has Y-mAbs Therapeutics issued on next quarter's earnings?: Y-mAbs Therapeutics updated its FY 2022 earnings guidance on Tuesday, September, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $45.00 million-$50.00 million, compared to the consensus revenue estimate of $60.18 million.

What other stocks do shareholders of Y-mAbs Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Y-mAbs Therapeutics investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Corbus Pharmaceuticals (CRBP), CTI BioPharma (CTIC), Nabriva Therapeutics (NBRV), Occidental Petroleum (OXY), VBI Vaccines (VBIV), Vaxart (VXRT) and Amarin (AMRN).
When did Y-mAbs Therapeutics IPO?: (YMAB) raised $80 million in an IPO on Friday, September 21st 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Canaccord Genuity acted as the underwriters for the IPO and BTIG was co-manager.
What is Y-mAbs Therapeutics' stock symbol?: Y-mAbs Therapeutics trades on the NASDAQ under the ticker symbol "YMAB."
How do I buy shares of Y-mAbs Therapeutics?: Shares of YMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Y-mAbs Therapeutics' stock price today?: One share of YMAB stock can currently be purchased for approximately $14.42.
How much money does Y-mAbs Therapeutics make?: Y-mAbs Therapeutics (NASDAQ:YMAB) has a market capitalization of $630.44 million and generates $34.90 million in revenue each year. The company earns $-55,280,000.00 in net income (profit) each year or ($3.09) on an earnings per share basis.
How many employees does Y-mAbs Therapeutics have?: The company employs 148 workers across the globe.
How can I contact Y-mAbs Therapeutics?: Y-mAbs Therapeutics' mailing address is 230 Park Avenue Suite 3350, NEW YORK NY, 10169. The official website for the company is www.ymabs.com. The company can be reached via phone at (646) 885-8505 or via email at info@ymabs.com.

This page (NASDAQ:YMAB) was last updated on 10/3/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Y-mAbs Therapeutics - YMAB Stock Forecast, Price & News

Y-mAbs Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month